Supreme Court overturns the Federal Circuit, granting more flexibility to biosimilar makers

Supreme Court overturns the Federal Circuit, granting more flexibility to biosimilar makers


In a unanimous opinion, the United States Supreme Court again reversed the Federal Circuit in Sandoz Inc. v. Amgen Inc. , interpreting the meaning of key provisions of the Biologics Price Competition and Innovation Act of 2009.



from Biotech News